The Haifa, Israel-based company has raised more than $70 million in a funding round.
IVD - News
Aromyx Corp. announces its groundbreaking biosensor technology based on the human sense of smell and taste. The company says the new technology has the potential to be used as a diagnostic tool to detect early stage cancer and disease.
Quadrant Biosciences scored a $2 million NIH grant to supports its epigenetic diagnostic test for autism spectrum disorder.
The study looked at nearly 1,048 patients to test the prognostic value of the VeriStrat test in patients with non-small cell lung cancer.
A new diagnostic system with digital imaging capabilities aims to enhance lab capabilities across the globe through multi-test processing, dry slide technology, and a full testing environment for accurate testing in a waterless environment.
FDA has given approval for the Roche’s cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests.
Personal Genome Diagnostics received a breakthrough device designation from FDA for the PGDx elio plasma resolve liquid biopsy test.
New research out of Bentley University aims to explore the genetic links between human DNA and opioid addiction. The new study could help doctors identify patients susceptible to opioid dependence and choose different treatment methods.
M&A activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.
Freenome has initiated a clinical study to help bring an AI-Genomics blood test for colorectal cancer to the U.S. market.
Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.
A new study shows proposed changes in the International Classification of Diseases (ICD) guidelines could lead to a reduction in the diagnosis of PTSD patients.